Does MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves Questions

It was a bad day to be a MannKind Corporation (NASDAQ:MNKD) investor yesterday after the biotech stock took an around 8% beating in the market on back of a dismal third quarter showing for diabetes drug Afrezza. Maxim analyst Jason Kolbert is shaking his head in frustration, relieved he recently ran to the sidelines.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts